Physician profile
Ellen C Vaughey
NPI 1346257219
$5,703.51
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $549 · 2021: $94.24 · 2022: $2,045 · 2023: $1,277 · 2024: $18.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.05 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $895.56 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $743.81 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.28 | 2019-2023 | Ofev |
| Genzyme Corporation | $458.27 | 2019-2023 | |
| Genentech USA, INC. | $247.46 | 2019-2023 | Xolair |
| Inari Medical, INC. | $242.79 | 2020 | |
| Janssen Pharmaceuticals, INC | $214.44 | 2019-2023 | Xarelto |
| Amgen INC. | $198.70 | 2021-2023 | Tezspire |
| Baxter Healthcare | $198.57 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $172.80 | 2019-2023 | Yupelri |
| Insmed, INC. | $159.09 | 2019-2023 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $150.07 | 2019-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $145.58 | 2019-2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $142.94 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.95 | 2022-2023 | Glassia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $116.76 | 2019-2022 | |
| Csl Behring | $110.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.84 | 2022-2023 | Acthar |
| Electromed, INC. | $99.84 | 2019-2023 | Smartvest |
| Philips North America LLC | $93.03 | 2019-2022 | |
| Gilead Sciences, INC. | $62.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.42 | 2019-2022 | |
| Pfizer INC. | $57.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.57 | 2019 | |
| United Therapeutics Corporation | $44.68 | 2019-2022 | |
| Vapotherm INC | $40.55 | 2022 | |
| Sunovion Pharmaceuticals INC. | $40.32 | 2019 | |
| Inogen, INC. | $36.90 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Circassia INC. | $36.70 | 2019 | |
| Merck Sharp & Dohme LLC | $28.54 | 2019-2020 | |
| Shionogi INC | $26.94 | 2023 | Fetroja |
| Paratek Pharmaceuticals, INC. | $21.62 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $20.78 | 2019 | |
| Pulmonx Corporation | $20.30 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Sanofi Pasteur INC. | $18.79 | 2019 | |
| Shire North American Group INC | $15.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Vaughey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.